CAJ | 학술논문

甲状腺未分化癌占甲状腺癌的1％~2％，死亡率高。就诊时肿瘤常已周围侵犯或远处转移而难以手术， R0/R1手术可以提高生存率。IMRT 放疗技术可以提高放疗剂量并保护正常组织。目前无标准化疗方案，放化疗联合应用可以延长部分患者生存。靶向治疗将成为未来研究的方向。深入精确分析 ATC 基因组、优化组合靶向治疗方法可以形成个体化精准医疗来提高生存。现对甲状腺未分化癌治疗策略作一综述。
갑상선미분화암점갑상선암적1％~2％，사망솔고。취진시종류상이주위침범혹원처전이이난이수술， R0/R1수술가이제고생존솔。IMRT 방료기술가이제고방료제량병보호정상조직。목전무표준화료방안，방화료연합응용가이연장부분환자생존。파향치료장성위미래연구적방향。심입정학분석 ATC 기인조、우화조합파향치료방법가이형성개체화정준의료래제고생존。현대갑상선미분화암치료책략작일종술。
Anaplastic thyroid carcinomas (ATC) had a high mortality rate. It accounted for 1% ~ 2% of all thyroid cancers. Surrounding invasion or distant metastasis was often found at the initial diagnosis of ATC patients, and thus made it difficult for the surgery treatment. Relatively, R0 / R1 surgery could relatively improve the survival rate. IMRT method could both increase the radiotherapy dose and simultaneously protect normal tissues. Currently, there was no standard chemotherapy. The combina-tion of radiotherapy and chemotherapy can prolong the survival time of some patients. Targeted therapy will become a hot re-search project in the future. Individual precise medical treatment will improve the survival by making in depth genomic analyses and optimizing combinatorial targeted therapy approaches for patients with ATC. In this article, we reviewed the treatment strat-egies for ATC patients.